Cencora is a US pharmaceutical distributor operating a high-volume, low-margin model across branded and generic drugs, injectables, and over-the-counter products. In 2025, it generated $321B in revenue and served tens of thousands of providers through a global network of 51,000 employees, including cold-chain specialty facilities.<\/p>\n
Revenue grew 7.5% year on year, with an 11% five-year average, and forecasts expect growth to continue through 2026 and 2027. Earnings have been more volatile, but remained positive; the company beat estimates over the last four quarters and the next four quarters are forecast to grow.<\/p>\n
Cencora holds long-term supply agreements, including a multi-billion contract with Walgreens Boots Alliance that accounted for roughly 24% of 2025 revenue and runs through 2029. In Q1 2026, it completed the acquisition of OneOncology.<\/p>\n
Following the deal, adjusted operating income guidance was raised to 11.5%\u201313.5% from 8%\u201310%. A 5% revenue increase in the US Healthcare Solutions segment in Q1 also supported the updated guidance.<\/p>\n
As of 13\/04\/2026, a Sigmanomics dashboard showed a bearish trade bias across 7-day, 14-day, and 28-day forecasts.<\/p>\n
Cencora presents a classic conflict between strong long-term fundamentals and a weak short-term outlook. We see consistent revenue growth, which we noted climbed to over $321 billion in 2025, and a recently raised guidance for 2026. However, the stock has seen a double-digit price decline, and near-term forecasts through late April and early May are bearish.<\/p>\n
Given this setup, simply buying the dip on COR shares or purchasing call options appears premature. The prevailing bearish sentiment for the coming weeks suggests any immediate rally is likely to be weak or fail. We should therefore consider strategies that benefit from sideways movement or a further slide in the stock price.<\/p>\n
This cautious stance is supported by market data showing a recent uptick in implied volatility for COR options, which has climbed to 29% from a low of 23% in February. This indicates the market is pricing in more uncertainty and potential price swings. This nervousness in the pharmaceutical distribution sector comes as traders await new federal guidance on drug purchasing programs expected next month.<\/p>\n
A practical approach for the next few weeks would be to sell out-of-the-money call spreads with expirations in May or June. This strategy allows us to collect premium based on the belief that the stock will not break out to the upside in the short term. It takes advantage of the elevated volatility while we wait for a clear bullish signal to emerge.<\/p>\n
This is not a bet against the company’s core strengths, such as the long-term Walgreens contract extending to 2029 or the margin-accretive OneOncology acquisition from earlier this year. Instead, it is a tactical play on timing, acknowledging that the market sentiment has not yet caught up with the underlying business case. We can also look at selling cash-secured puts at a strike price significantly below the current level, which would allow us to either keep the premium or acquire the stock at a more attractive price if the bearish trend continues.<\/p>\n","protected":false},"excerpt":{"rendered":"
Cencora, major US drug distributor, grew revenue to $321B; Walgreens deal, OneOncology acquisition, raised outlook amid bearish bias.<\/p>\n","protected":false},"author":103,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-47682","post","type-post","status-publish","format-standard","hentry","category-live-updates"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\n\t\t